Noninvasive Electroencephalogram (EEG) — Commercial/Medicaid

Effective Date: August 8, 2020       Number: MG.MM.ME.77

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to Health Insurance Plan of Greater New York, and Group Health Incorporated, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Background

A noninvasive Electroencephalogram (EEG) records electrical activity of the brain via scalp electrodes. An EEG can be used to confirm a diagnosis of epilepsy and classify it as partial (focal) or generalized. The EEG is also helpful in the evaluation and management of comatose and impaired cognitive states. A normal EEG does not necessarily exclude the diagnosis of epilepsy, and an abnormal EEG may be unrelated to the patient's clinical presentation.

Guideline

Noninvasive (scalp) EEG may be indicated for 1 or more of the following:

- Brain death determination
- Change in neurologic status (eg, altered mental status, confusional state, delirium, encephalopathy, impaired cognition)
- Comatose patient after cardiac resuscitation
- Differentiation of epileptic from nonepileptic events
- Epilepsy, known, and need for repeat evaluation, as indicated by 1 or more of the following:
  - Change in clinical status (eg, new symptoms)
  - Focal epilepsy, and need to characterize location of seizure
  - Withdrawal of anticonvulsant medication under consideration
- Epilepsy, suspected, and need for repeat evaluation after nondiagnostic initial EEG but persistent high clinical suspicion
- Epilepsy or nonfebrile infantile spasms (ie, West syndrome), suspected new onset

---

1 Epilepsy is defined by any of the following: At least 2 unprovoked or reflex seizures occurring greater than 24 hours apart; one unprovoked or reflex seizure and a 60% or greater probability of further seizures occurring over the next 10 years; or diagnosis of an epilepsy syndrome.
Intracranial infection, suspected, as indicated by 1 or more of the following:
  - Bovine spongiform encephalopathy
  - Creutzfeldt-Jakob disease
  - Herpes simplex encephalitis
  - Subacute sclerosing panencephalitis

- Persistent vegetative state or other disorder of consciousness
- Seizures associated with abnormal mental status or focal neurologic deficit
- Syncope with atypical features, as indicated by 1 or more of the following:
  - Automatisms (eg, chewing, lip smacking)
  - Blue face during episode
  - Clonic movements, one-sided
  - Confusion after episode, prolonged
  - Tongue biting during episode
  - Tonic-clonic movements that were prolonged and began at same time as loss of consciousness

Limitations/Exclusions

(See Medical Necessity Guidelines: Experimental, Investigational or Unproven Services or table below)

EEG is considered experimental, investigational or unproven for following (list not all-inclusive):

- Alzheimer disease
- Attention-deficit hyperactivity disorder (ADD/ADHD)
- Autism spectrum disorders
- Depression
- Febrile seizures in children
- Headache
- Posttraumatic Stress disorder (PTSD)
- Preterm infant neurodevelopmental prognostic evaluation

---

For Alzheimer disease, evidence is insufficient, conflicting, or poor and demonstrates an incomplete assessment of net benefit vs harm; additional research is recommended. A literature review states that resting state EEG has variable accuracy in differentiating Alzheimer disease from mild cognitive impairment or normal healthy older patients, limiting its role as a stand-alone population screening tool.

For attention-deficit hyperactivity disorder, evidence is insufficient, conflicting, or poor and demonstrates an incomplete assessment of net benefit vs harm; additional research is recommended. A systematic review found insufficient evidence to recommend EEG-based tests for the diagnosis of attention-deficit hyperactivity disorder due to limited studies that have variable and inconsistent findings. Review articles state that although some studies have shown a relationship between the EEG theta:beta ratio and attention-deficit hyperactivity disorder, other studies have questioned its use as a reliable diagnostic marker. Additional research is needed to better characterize any potential diagnostic utility of the theta:beta ratio. A specialty society practice guideline states that the EEG theta:beta ratio has an unacceptably high false-positive rate compared with clinical evaluation and should not be used for the diagnosis of attention-deficit hyperactivity disorder.

For autism spectrum disorders, evidence is insufficient, conflicting, or poor and demonstrates an incomplete assessment of net benefit vs harm; additional research is recommended. Review articles state that although several studies have utilized EEG wave patterns to differentiate patients with autism spectrum disorders from normal controls, these measures have not been validated as being sensitive or specific for the diagnosis of autism.

For depression, evidence is insufficient, conflicting, or poor and demonstrates an incomplete assessment of net benefit vs harm; additional research is recommended. A review article states that although resting state EEG holds promise as a means of predicting and optimizing antidepressant treatment outcomes, its specificity in predicting response to a particular
intervention remains uncertain. Another review article notes that although the use of EEG parameters as a biomarker appears intriguing, randomized controlled trials are required to compare outcomes for EEG-guided and therapist-guided treatment decisions.

For febrile seizures in children, evidence demonstrates a lack of net benefit; additional research is recommended. An evidence-based review states that EEG is of limited value in the evaluation of febrile seizures; although abnormalities may be present on EEG, their clinical significance is unclear in terms of predicting febrile seizure recurrence or the development of epilepsy. Practice guidelines and review articles have concluded that EEG is not recommended for simple febrile seizures in children with normal neurologic examinations. A systematic review found that there were no randomized controlled trials to support or refute the use of EEG and determine its optimal timing after complex febrile seizures in children.

For headache, evidence demonstrates a lack of net benefit; additional research is recommended. A national neurology specialty society recommends against the use of EEG in the evaluation of headaches, citing the lower sensitivity of electroencephalography in detecting structural lesions, as compared with CT scan or MRI, lack of demonstrable value in diagnosing migraine headaches, and the potential for discovery of incidental findings that would require performing unnecessary procedures and treatment. An evidence-based specialty society consensus guideline states that EEG is not considered to be useful in the investigation of headache.

For posttraumatic stress disorder, evidence is insufficient, conflicting, or poor and demonstrates an incomplete assessment of net benefit vs harm; additional research is recommended. A systematic review of 34 studies evaluating the efficacy of EEG wave patterns for assessment of the severity of symptoms of posttraumatic stress disorder concluded that although their use seems promising, additional studies are necessary to confirm the findings.

For preterm infant neurodevelopmental prognostic evaluation, evidence is insufficient, conflicting, or poor and demonstrates an incomplete assessment of net benefit vs harm; additional research is recommended. A systematic review and meta-analysis of 13 studies (1181 preterm infants) evaluating the predictive accuracy of EEG background activity for neurodevelopmental outcomes 1 to 10 years after birth concluded that although EEG may have potential as a surrogate marker for neurodevelopmental outcomes, additional high-quality studies were recommended to confirm the findings.

Revision History

May 8, 2020 | New policy eff. Aug. 8, 2020

Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>95812</td>
<td>Electroencephalogram (EEG) extended monitoring; 41-60 minutes</td>
</tr>
<tr>
<td>95813</td>
<td>Electroencephalogram (EEG) extended monitoring; 61-119 minutes</td>
</tr>
<tr>
<td>95816</td>
<td>Electroencephalogram (EEG); including recording awake and drowsy</td>
</tr>
<tr>
<td>95819</td>
<td>Electroencephalogram (EEG); including recording awake and asleep</td>
</tr>
<tr>
<td>95822</td>
<td>Electroencephalogram (EEG); recording in coma or sleep only</td>
</tr>
<tr>
<td>95824</td>
<td>Electroencephalogram (EEG); cerebral death evaluation only</td>
</tr>
<tr>
<td>95957</td>
<td>Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis)</td>
</tr>
</tbody>
</table>

Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A81.00</td>
<td>Creutzfeldt-Jakob disease, unspecified</td>
</tr>
<tr>
<td>A81.01</td>
<td>Variant Creutzfeldt-Jakob disease</td>
</tr>
<tr>
<td>A81.09</td>
<td>Other Creutzfeldt-Jakob disease</td>
</tr>
<tr>
<td>F05</td>
<td>Delirium due to known physiological condition</td>
</tr>
<tr>
<td>F44.5</td>
<td>Conversion disorder with seizures or convulsions</td>
</tr>
<tr>
<td>F44.6</td>
<td>Conversion disorder with sensory symptom or deficit</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>F44.7</td>
<td>Conversion disorder with mixed symptom presentation</td>
</tr>
<tr>
<td>F44.89</td>
<td>Other dissociative and conversion disorders</td>
</tr>
<tr>
<td>F84.2</td>
<td>Rett's syndrome</td>
</tr>
<tr>
<td>G40.001</td>
<td>Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.009</td>
<td>Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.011</td>
<td>Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.019</td>
<td>Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.101</td>
<td>Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.109</td>
<td>Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.111</td>
<td>Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.119</td>
<td>Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.201</td>
<td>Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.209</td>
<td>Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.211</td>
<td>Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.219</td>
<td>Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.301</td>
<td>Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.309</td>
<td>Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.311</td>
<td>Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.319</td>
<td>Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.401</td>
<td>Other generalized epilepsy and epileptic syndromes, not intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.409</td>
<td>Other generalized epilepsy and epileptic syndromes, not intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.411</td>
<td>Other generalized epilepsy and epileptic syndromes, intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.419</td>
<td>Other generalized epilepsy and epileptic syndromes, intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.501</td>
<td>Epileptic seizures related to external causes, not intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.509</td>
<td>Epileptic seizures related to external causes, not intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.801</td>
<td>Other epilepsy, not intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.802</td>
<td>Other epilepsy, not intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.803</td>
<td>Other epilepsy, intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.804</td>
<td>Other epilepsy, intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.811</td>
<td>Lennox-Gastaut syndrome, not intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.812</td>
<td>Lennox-Gastaut syndrome, not intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.813</td>
<td>Lennox-Gastaut syndrome, intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.814</td>
<td>Lennox-Gastaut syndrome, intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.821</td>
<td>Epileptic spasms, not intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.822</td>
<td>Epileptic spasms, not intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.823</td>
<td>Epileptic spasms, intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.824</td>
<td>Epileptic spasms, intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.89</td>
<td>Other seizures</td>
</tr>
<tr>
<td>G40.901</td>
<td>Epilepsy, unspecified, not intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.909</td>
<td>Epilepsy, unspecified, not intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.911</td>
<td>Epilepsy, unspecified, intractable, with status epilepticus</td>
</tr>
</tbody>
</table>
G40.919 Epilepsy, unspecified, intractable, without status epilepticus
G40.A01 Absence epileptic syndrome, not intractable, with status epilepticus
G40.A09 Absence epileptic syndrome, not intractable, without status epilepticus
G40.A11 Absence epileptic syndrome, intractable, with status epilepticus
G40.A19 Absence epileptic syndrome, intractable, without status epilepticus
G40.B01 Juvenile myoclonic epilepsy, not intractable, with status epilepticus
G40.B09 Juvenile myoclonic epilepsy, not intractable, without status epilepticus
G40.B11 Juvenile myoclonic epilepsy, intractable, with status epilepticus
G40.B19 Juvenile myoclonic epilepsy, intractable, without status epilepticus
G47.51 Confusional arousals
G93.40 Encephalopathy, unspecified
R41.82 Altered mental status, unspecified
R56.1 Post traumatic seizures

References


90. Specialty matched clinical peer review.